Aberrant expressions of IL-33 and/or ST2 has been well documented in plentiful inflammatory disorders, such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease (37). This evidence concerns the gene IL33 and multiple sclerosis.